Abbott Laboratories Q1 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ABT?
Source: Yahoo Finance
- Adjusted EPS Performance: Abbott Laboratories reported an adjusted earnings per share of $1.15 for Q1, aligning with guidance despite earlier-than-expected financing costs and a weaker respiratory season, demonstrating the company's resilience under challenging conditions.
- Medical Devices Sales Growth: The Medical Devices segment saw an 8.5% sales increase, driven by strong performance in cardiovascular devices, with double-digit growth in electrophysiology and heart failure products, indicating the company's market leadership in critical areas.
- Cancer Diagnostics Expansion: Cancer diagnostics sales grew by 13% year-over-year, with the acquisition of Exact Sciences expected to add approximately $3 billion in sales by 2026, further solidifying Abbott's competitive edge in cancer detection.
- Market Challenges and Outlook: Despite a 10% decline in sales for rapid and molecular diagnostics due to reduced demand for respiratory virus testing, Abbott remains optimistic about growth in the second half of the year, planning to leverage strategic initiatives in nutrition, electrophysiology, and core lab diagnostics to drive performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 101.560
Low
136.00
Averages
148.11
High
169.00
Current: 101.560
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott Laboratories Reports Mixed Q1 2026 Earnings Amid Lowered EPS Outlook
- Revenue Growth: Abbott Laboratories reported an approximately 8% year-over-year revenue increase in Q1 2026, reaching $11.2 billion, surpassing consensus estimates by $160 million, primarily driven by a notable 13% growth in its MedTech division, marking the company's first top-line beat in two quarters.
- Lowered EPS Outlook: Despite the revenue beat, Abbott has revised its 2026 adjusted diluted EPS outlook down to $5.38–$5.58 from the previous range of $5.55–$5.80, largely due to a $21 billion acquisition of Exact Sciences that introduced $0.20 per share dilution, resulting in a decline in share price during trading.
- Declining Market Rating: Abbott ranks last among the top 10 large-cap U.S. healthcare equipment stocks according to Seeking Alpha's Quant Rating, with a score of just 2.86, reflecting headwinds from diluted guidance, an underperforming Nutrition segment, and compressed gross margins.
- Future Sales Growth Forecast: The company forecasts a comparable sales growth of 6.5%-7.5% for 2026, while integrating Exact Sciences with a projected $0.20 EPS dilution, indicating that Abbott aims to maintain growth expectations despite facing significant challenges.
See More
Abbott's Shares Decline 2% in Premarket Trading Following Q1 Results
- Market Reaction: Shares of the company fell by 2% in pre-market trading following the release of Q1 results.
- Earnings Report: The Q1 results have influenced investor sentiment, leading to a decline in stock prices.
See More
Abbott Laboratories Q1 Earnings Highlights
- Adjusted EPS Performance: Abbott Laboratories reported an adjusted earnings per share of $1.15 for Q1, aligning with guidance despite earlier-than-expected financing costs and a weaker respiratory season, demonstrating the company's resilience under challenging conditions.
- Medical Devices Sales Growth: The Medical Devices segment saw an 8.5% sales increase, driven by strong performance in cardiovascular devices, with double-digit growth in electrophysiology and heart failure products, indicating the company's market leadership in critical areas.
- Cancer Diagnostics Expansion: Cancer diagnostics sales grew by 13% year-over-year, with the acquisition of Exact Sciences expected to add approximately $3 billion in sales by 2026, further solidifying Abbott's competitive edge in cancer detection.
- Market Challenges and Outlook: Despite a 10% decline in sales for rapid and molecular diagnostics due to reduced demand for respiratory virus testing, Abbott remains optimistic about growth in the second half of the year, planning to leverage strategic initiatives in nutrition, electrophysiology, and core lab diagnostics to drive performance.
See More
Three Companies' Shares Drop Amid Dimming Market Outlook
- LCID Share Decline: Lucid Group (LCID) shares fell 6% on Thursday, marking a third consecutive day of decline, as TD Cowen and Baird lowered their price targets to $10 and $12 respectively, reflecting investor concerns over the auto market outlook, particularly after the company's recent $1.05 billion capital raise, which has pressured market confidence.
- ABT Earnings Outlook Cut: Abbott Laboratories (ABT) shares experienced their worst session in nearly three months on Thursday after the company revised its 2026 EPS outlook down to $5.38-$5.58 from $5.55-$5.80, primarily due to the impact of its $23 billion acquisition of Exact Sciences, indicating sluggish growth in its nutrition and medical device segments.
- ASBP Shareholder Approval for Capital Expansion: Aspire Biopharma Holdings (ASBP) shares plummeted 45% after shareholders approved a reverse stock split and additional equity issuance, reflecting market concerns over dilution risks and significant funding needs, while the company plans to acquire Dura Driver Control Systems for $30 million to expand its business.
- Retail Investor Sentiment Analysis: Despite LCID and ABT being viewed as “extremely bullish” on Stocktwits, ASBP's sentiment was rated as “bullish,” contrasting sharply with the significant declines over the past year, where LCID fell 67%, ABT dropped 25%, and ASBP plummeted 99%, indicating a lack of confidence in future growth prospects.
See More
Abbott's Q1 Results Meet Expectations but Guidance Cut Damps Sentiment
- Sales Performance: Abbott's Q1 sales totaled nearly $11.2 billion, reflecting an almost 8% year-over-year increase; however, despite meeting analyst expectations, the stock fell by 6% as investors reacted negatively to the results.
- Net Income Stability: The company's net income under GAAP rose modestly by 5% to just over $2 million, or $1.15 per share, indicating stable profitability, yet this was insufficient to bolster investor confidence in the stock.
- Guidance Downgrade: Abbott lowered its full-year 2026 adjusted EPS guidance to $5.38 to $5.58, down from the previous forecast of $5.55 to $5.80, reflecting a cautious outlook on profitability, particularly due to anticipated share dilution from the Exact Sciences acquisition.
- Medical Devices Growth: Abbott's medical devices segment saw a 13% year-over-year sales increase, with double-digit growth in electrophysiology, rhythm management, diabetes care, and heart failure products, showcasing strong performance in this area despite the overall market's negative sentiment.
See More
Abbott Lowers Full-Year Profit Guidance, Stock Drops
- Performance Overview: Abbott's Q1 sales reached nearly $11.2 billion, an 8% year-over-year increase, but net income only grew modestly by 5% to just over $2 million, indicating pressure on profitability.
- Guidance Cut: The company lowered its 2026 adjusted EPS forecast to $5.38 to $5.58, down from $5.55 to $5.80, reflecting a cautious outlook on future profitability amid market uncertainties.
- Market Reaction: Following the significant guidance cut, Abbott's stock fell by 6% after the earnings release, as investor concerns about future prospects intensified, leading to a negative market sentiment.
- Medical Devices Performance: Despite the overall disappointing results, Abbott's medical devices segment saw a 13% sales increase, indicating strong demand in this area, which may support the company's future growth.
See More
Abbott Laboratories Reports Mixed Q1 2026 Earnings Amid Lowered EPS Outlook
- Revenue Growth: Abbott Laboratories reported an approximately 8% year-over-year revenue increase in Q1 2026, reaching $11.2 billion, surpassing consensus estimates by $160 million, primarily driven by a notable 13% growth in its MedTech division, marking the company's first top-line beat in two quarters.
- Lowered EPS Outlook: Despite the revenue beat, Abbott has revised its 2026 adjusted diluted EPS outlook down to $5.38–$5.58 from the previous range of $5.55–$5.80, largely due to a $21 billion acquisition of Exact Sciences that introduced $0.20 per share dilution, resulting in a decline in share price during trading.
- Declining Market Rating: Abbott ranks last among the top 10 large-cap U.S. healthcare equipment stocks according to Seeking Alpha's Quant Rating, with a score of just 2.86, reflecting headwinds from diluted guidance, an underperforming Nutrition segment, and compressed gross margins.
- Future Sales Growth Forecast: The company forecasts a comparable sales growth of 6.5%-7.5% for 2026, while integrating Exact Sciences with a projected $0.20 EPS dilution, indicating that Abbott aims to maintain growth expectations despite facing significant challenges.
See More
Abbott's Shares Decline 2% in Premarket Trading Following Q1 Results
- Market Reaction: Shares of the company fell by 2% in pre-market trading following the release of Q1 results.
- Earnings Report: The Q1 results have influenced investor sentiment, leading to a decline in stock prices.
See More
Abbott Laboratories Q1 Earnings Highlights
- Adjusted EPS Performance: Abbott Laboratories reported an adjusted earnings per share of $1.15 for Q1, aligning with guidance despite earlier-than-expected financing costs and a weaker respiratory season, demonstrating the company's resilience under challenging conditions.
- Medical Devices Sales Growth: The Medical Devices segment saw an 8.5% sales increase, driven by strong performance in cardiovascular devices, with double-digit growth in electrophysiology and heart failure products, indicating the company's market leadership in critical areas.
- Cancer Diagnostics Expansion: Cancer diagnostics sales grew by 13% year-over-year, with the acquisition of Exact Sciences expected to add approximately $3 billion in sales by 2026, further solidifying Abbott's competitive edge in cancer detection.
- Market Challenges and Outlook: Despite a 10% decline in sales for rapid and molecular diagnostics due to reduced demand for respiratory virus testing, Abbott remains optimistic about growth in the second half of the year, planning to leverage strategic initiatives in nutrition, electrophysiology, and core lab diagnostics to drive performance.
See More
Three Companies' Shares Drop Amid Dimming Market Outlook
- LCID Share Decline: Lucid Group (LCID) shares fell 6% on Thursday, marking a third consecutive day of decline, as TD Cowen and Baird lowered their price targets to $10 and $12 respectively, reflecting investor concerns over the auto market outlook, particularly after the company's recent $1.05 billion capital raise, which has pressured market confidence.
- ABT Earnings Outlook Cut: Abbott Laboratories (ABT) shares experienced their worst session in nearly three months on Thursday after the company revised its 2026 EPS outlook down to $5.38-$5.58 from $5.55-$5.80, primarily due to the impact of its $23 billion acquisition of Exact Sciences, indicating sluggish growth in its nutrition and medical device segments.
- ASBP Shareholder Approval for Capital Expansion: Aspire Biopharma Holdings (ASBP) shares plummeted 45% after shareholders approved a reverse stock split and additional equity issuance, reflecting market concerns over dilution risks and significant funding needs, while the company plans to acquire Dura Driver Control Systems for $30 million to expand its business.
- Retail Investor Sentiment Analysis: Despite LCID and ABT being viewed as “extremely bullish” on Stocktwits, ASBP's sentiment was rated as “bullish,” contrasting sharply with the significant declines over the past year, where LCID fell 67%, ABT dropped 25%, and ASBP plummeted 99%, indicating a lack of confidence in future growth prospects.
See More
Abbott's Q1 Results Meet Expectations but Guidance Cut Damps Sentiment
- Sales Performance: Abbott's Q1 sales totaled nearly $11.2 billion, reflecting an almost 8% year-over-year increase; however, despite meeting analyst expectations, the stock fell by 6% as investors reacted negatively to the results.
- Net Income Stability: The company's net income under GAAP rose modestly by 5% to just over $2 million, or $1.15 per share, indicating stable profitability, yet this was insufficient to bolster investor confidence in the stock.
- Guidance Downgrade: Abbott lowered its full-year 2026 adjusted EPS guidance to $5.38 to $5.58, down from the previous forecast of $5.55 to $5.80, reflecting a cautious outlook on profitability, particularly due to anticipated share dilution from the Exact Sciences acquisition.
- Medical Devices Growth: Abbott's medical devices segment saw a 13% year-over-year sales increase, with double-digit growth in electrophysiology, rhythm management, diabetes care, and heart failure products, showcasing strong performance in this area despite the overall market's negative sentiment.
See More
Abbott Lowers Full-Year Profit Guidance, Stock Drops
- Performance Overview: Abbott's Q1 sales reached nearly $11.2 billion, an 8% year-over-year increase, but net income only grew modestly by 5% to just over $2 million, indicating pressure on profitability.
- Guidance Cut: The company lowered its 2026 adjusted EPS forecast to $5.38 to $5.58, down from $5.55 to $5.80, reflecting a cautious outlook on future profitability amid market uncertainties.
- Market Reaction: Following the significant guidance cut, Abbott's stock fell by 6% after the earnings release, as investor concerns about future prospects intensified, leading to a negative market sentiment.
- Medical Devices Performance: Despite the overall disappointing results, Abbott's medical devices segment saw a 13% sales increase, indicating strong demand in this area, which may support the company's future growth.
See More
